SOX2 in squamous cell carcinoma: Amplifying a pleiotropic oncogene along carcinogenesis

Hussenet, Thomas; Manoir, Stanislas du

doi:10.4161/cc.9.8.11203

Cited by 82 publications

(57 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…8 Recent studies have provided strong evidence that SOX2 is the primary amplification target within the common 3q amplicon and functional studies using shRNA against SOX2 showed an impact on tumor biology, thus making SOX2 the most promising candidate 3q oncogene. 9,10,28 We found SOX2 amplification to be associated with higher SOX2 expression in lung squamous cell carcinomas, likely reflecting a gene dosage effect. While this association was highly significant, there were a few cases with high SOX2 expression levels despite the absence of SOX2 amplification, indicating that in some instances mechanisms other than SOX2 copy number may explain SOX2 protein overexpression.…”

Section: Sox2 In Lung Squamous Cell Carcinomasmentioning

confidence: 71%

“…11 Besides its role during neurogenesis and embryonic foregut development, SOX2 can aid the reprogramming of adult cells into induced pluripotent stem cells, indicating a major potency for induction of cellular fate changes. 12,14,28 More recently, studies have identified SOX2 as the driving gene of the well-known 3q amplicon in squamous cell carcinomas of the lung and the esophagus, suggesting SOX2 as a novel candidate oncogene 9,10 in lung carcinogenesis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer

Wilbertz¹,

Wagner

Petersen³

et al. 2011

Modern Pathology

168

155

View full text Add to dashboard Cite

The transcription factor SOX2 (3q26.3-q27) is a key regulator of foregut development and an embryonic stem cell factor cooperating during induction of pluripotency in terminally differentiated somatic cells. Recently, we found SOX2 to be amplified in a subset of squamous cell lung and esophageal cancers. The aim of this study was to explore the prognostic role of SOX2 in a large series of squamous cell carcinomas and adenocarcinomas of the lung. A total of 891 samples from two independent population-based cohorts were assessed by fluorescence in situ hybridization and immunohistochemistry. Furthermore, we assessed for associations between SOX2 amplification/upregulation and clinicopathological features. Similar results were found in the two cohorts. Within squamous cell carcinoma cases, 8% high-level as well as 68 and 65% low-level SOX2 amplifications occurred in the two cohorts, respectively. In adenocarcinomas, no high-level amplification was found and low-level amplification occurred in 6% of the two cohorts. Within squamous cell carcinomas of one cohort, SOX2 amplification was associated with lower tumor grade, while higher levels of SOX2 expression were related to younger age, smaller tumor size, and lower probability of angiolymphatic invasion and metastasis. High SOX2 expression levels proved to be a marker for prolonged overall survival among patients with squamous cell carcinomas. In conclusion, SOX2 amplification and upregulation are frequent events in squamous cell carcinomas of the lung and are associated with indicators of favorable prognosis. Modern Pathology (2011) 24, 944-953;

show abstract

Section: Sox2 In Lung Squamous Cell Carcinomasmentioning

confidence: 71%

Section: Discussionmentioning

confidence: 99%

SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer

Wilbertz¹,

Wagner

Petersen³

et al. 2011

Modern Pathology

168

155

View full text Add to dashboard Cite

show abstract

“…SOX2 overexpression was more prevalent in SCCs than in ADCs. SOX2 is reported to be a master pluripotency controller and has recently been identified as a novel major oncogene, recurrently amplified and activated in SCC (43,44). These studies have used a similar strategy of chromosomal aberrations screening to identify the SOX2 locus as one of the most frequently amplified sites over the SCC genome.…”

Section: Discussionmentioning

confidence: 99%

Expression of MET and SOX2 genes in non-small cell lung carcinoma with EGFR mutation

Cai

Zhang²,

Qu³

et al. 2011

Oncol Rep

View full text Add to dashboard Cite

Abstract. Non-small cell lung carcinoma (NSCLC) is a leading cause of cancer-related deaths. Aberrance of the two oncogenes MET and SOX2 are frequently encountered in NSCLC. Exons 18 through 21 of the EGFR gene were screened and MET and SOX2 immunostaining was conducted to analyze the immunohistological staining of MET and SOX2 and the EGFR mutation status. One hundred and fifty tissue samples were examined including 57 squamous cell carcinomas (SCCs), 80 adenocarcinomas (ADCs), 9 adenosquamous carcinomas (ADSCs) and 4 large cell carcinomas (LCCs). The 32 NSCLCs harboring an EGFR mutation included 28 ADCs, 3 SCCs and 1 ADSC. A higher level of SOX2 expression appeared in NSCLCs without the EGFR mutation compared to those with EGFR mutation (χ 2 =9.02, P=0.0027). Of the 28 ADCs, 24 (85.7%) with an EGFR mutation showed low level of SOX2 expression. ADCs with deletion in exon 19 overexpressed MET and showed low levels of SOX2. SOX2 expression was inversely correlated to the expression of MET in NSCLC and mainly present in non-mutated NSCLC (r=-0.42, P<0.0001). There was a tendency for SOX2 to be expressed in SCCs and particularly in the part of SCC among ADSCs, whereas MET was mainly expressed in the part of ADC among ADSCs and ADCs. High level of MET and SOX2 expression were respectively demonstrated in ADCs and SCCs; MET activation was accompanied with exon 19 deletion in ADCs. EGFR and MET coordinate to drive tumorigenesis. Detection of the activation of MET and EGFR may be used for targeted drug therapy.

show abstract

“…Sox2 protein ifadesinin hipofarinks ve larinks tümörlerinin başlamasında etkili olmasına karşın, ilerlemesinde rolü olmadığı belirtilmektedir (41). Sox2 amplifikasyonu glioblastoma, küçük hücreli akciğer kanseri ve pek çok farklı tip skuamöz hücreli kanserlerde gösterilmiştir (42)(43)(44)(45). Başka bir çalışmada, CDC20-APC'nin, insan glioblastoma kök hücrelerinde invazyon ve kendini yenileme özelliğini Sox2 ifadesini kontrol ederek düzenlediği belirlenmiştir (46).…”

Section: Sox2'nin Tümör Başlamasında Ve Gelişiminde Rolüunclassified

Kanserde yeni bir hedef haline gelen çok yönlü Sox2 geni

Turaçlı¹,

Ekmekçi²

2016

Ege Tıp Dergisi

View full text Add to dashboard Cite

ÖzSox2 proteini, farklılaşmamış erken embriyo kök hücrelerinin ve çeşitli yetişkin kök hücrelerinin gelişimi ve devamlılığının düzenlenmesinde rol oynayan bir transkripsiyon faktörüdür. Sox2, diğer pluripotensi faktörleri gibi posttranskripsiyonel ve post-translasyonel değişimlere uğramakta, böylece DNA'ya bağlanma aktivitesi değişebilmektedir. Sox2, kanser hücrelerinin çoğalması, invazyon, göç ve metastazında, tümör hücre ve kök hücre statüsünün devamında, hücresel programlama, apoptoz ve kemodirenç gelişimi gibi pek çok kanser aşamasında yer almaktadır. Bazı farklı bulgulara karşın çoğunlukla Sox2'nin kanser hücrelerinde anti-apoptotik bir faktör olarak çalıştığı konusunda uzlaşma vardır. Bu derlemede, Sox2'nin kök hücre devamlılığı, farklılaşması ve sinyal iletimindeki rollerini, bunun yanında gen çoğalmasıyla onkojenik özelliği kazanmasını ve moleküler hedef olarak kullanılma potansiyelini de kapsayan çok yönlü özelliklerini kısaca tartışacağız.Anahtar Sözcükler: Sox2, kanser. Abstract Sox2 protein is a transcription factor which is important for the maintenance and regulation of the permanence of undifferentiated embryonic and adult stem cells. Like the other pluripotency factors, Sox2 can be regulated by posttranscriptional and post-translational modifications which affect its binding ability to DNA. Sox2 involves in many cellular events in the initiation and progression of tumorigenesis such as proliferation of cancer cells, invasion

show abstract

SOX2 in squamous cell carcinoma: Amplifying a pleiotropic oncogene along carcinogenesis

Cited by 82 publications

References 31 publications

SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer

SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer

Expression of MET and SOX2 genes in non-small cell lung carcinoma with EGFR mutation

Kanserde yeni bir hedef haline gelen çok yönlü Sox2 geni

Contact Info

Product

Resources

About